Business Context and Reporting Period
This Form 8-K filing by AlloVir, Inc. (not Kalaris Therapeutics, Inc.) reports on the Annual Meeting of Stockholders held on May 25, 2021. The company is incorporated in Delaware and trades on the Nasdaq Global Select Market under the symbol ALVR.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
As of the record date (March 29, 2021), there were 65,106,873 shares of common stock outstanding. Stockholders approved two proposals:
- Proposal 1 (Director Election): Election of Juan Vera, M.D., Ansbert Gadicke, M.D., and Morana Jovan-Embiricos, Ph.D. as Class I directors.
- Proposal 2 (Auditor Ratification): Ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021.
| Proposal | For | Against/Withhold | Abstain/Non-Votes |
|---|---|---|---|
| Proposal 1 (Directors) | Varied by nominee (approx. 54M-56M) | Varied by nominee (approx. 1.7M-4.0M) | 3,615,172 (Broker Non-Votes) |
| Proposal 2 (Auditor) | 61,423,390 | 109,452 | 20,854 |
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting outcomes.
Investor Verification Checklist
- Verify the company name is AlloVir, Inc. (ALVR), as the request metadata incorrectly listed Kalaris Therapeutics.
- Confirm the election of the three Class I directors serving until the 2024 Annual Meeting.
- Review the Definitive Proxy Statement filed on April 12, 2021, for detailed biographical information on the elected directors.
- Note that no financial performance data is contained in this specific 8-K filing.